Exposure-response (E-R) analysis of efficacy for avelumab in combination with axitinib in patients with advanced renal cell carcinoma (aRCC) in JAVELIN Renal 101.

被引：0
|
作者：
Bello, Carlo [1 ]
Brar, Satjit [1 ]
Masters, Joanna C. [2 ]
Khandelwal, Akash [3 ]
Novakovic, Ana M. [3 ]
Ruiz-Garcia, Ana [1 ]
Hibma, Jennifer [2 ]
机构：
[1] Pfizer Inc, San Diego, CA USA
[2] Pfizer Inc, La Jolla, CA USA
[3] Merck KGaA, Darmstadt, Germany
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Randomized phase III trial of avelumab plus axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis
    Uemura, M.
    Tomita, Y.
    Miyake, H.
    Hatakeyama, S.
    Kanayama, H-O.
    Numakura, K.
    Takagi, T.
    Kato, T.
    Eto, M.
    Obara, W.
    Uemura, H.
    Motzer, R. J.
    Fujii, Y.
    Kamei, Y.
    Oya, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial
    Grimm, Marc-Oliver
    Oya, Mototsugu
    Choueiri, Toni K.
    Motzer, Robert J.
    Schmidinger, Manuela
    Quinn, David I.
    Gravis-Mescam, Gwenaelle
    Verzoni, Elena
    Van den Eertwegh, Alfonsus J. M.
    di Pietro, Alessandra
    Mariani, Mariangela
    Wang, Jing
    Thomaidou, Despina
    Albiges, Laurence
    EUROPEAN UROLOGY, 2024, 85 (01) : 8 - 12
  • [33] Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): Results from JAVELIN Renal 101
    Grimm, M-O.
    Oya, M.
    Choueiri, T. K.
    Schmidinger, M.
    Quinn, D. I.
    Mescam, G. Gravis
    Verzoni, E.
    Van den Eertwegh, A. J. M.
    di Pietro, A.
    Mariani, M.
    Wang, J.
    Thomaidou, D.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S690 - S691
  • [34] Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): results from JAVELIN Renal 101
    Grimm, Marc-Oliver
    Oya, Mototsugu
    Choueiri, Toni K.
    Schmidinger, Manuela
    Quinn, David
    Gravis-Mescam, Gwenaelle
    Verzoni, Elena
    Van den Eertwegh, Alfonsus
    Di Pietro, Alessandra
    Mariani, Mariangela
    Wang, Jing
    Thomaidou, Despina
    Albiges, Laurence
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 100 - 100
  • [35] Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
    Bilen, Mehmet A.
    Rini, Brian, I
    Voss, Martin H.
    Larkin, James
    Haanen, John B. A. G.
    Albiges, Laurence
    Pagliaro, Lance C.
    Voog, Eric G.
    Lam, Elaine T.
    Kislov, Nikolay
    McGregor, Bradley A.
    Lalani, Aly-Khan A.
    Huang, Bo
    di Pietro, Alessandra
    Krulewicz, Stan
    Robbins, Paul B.
    Choueiri, Toni K.
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 738 - 747
  • [36] Ipilimumab Exposure-Response (E-R) Analysis of Overall Survival (OS) in Patients with Advanced Melanoma
    Vezina, Heather E.
    Feng, Yan
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S28 - S28
  • [37] Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
    Lacy, Steven
    Nielsen, Jace
    Yang, Bei
    Miles, Dale
    Linh Nguyen
    Hutmacher, Matt
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1061 - 1070
  • [38] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.
    Froehner, Michael
    EUROPEAN UROLOGY, 2024, 86 (05)
  • [39] AN INCREMENTAL EFFECTIVENESS ANALYSIS OF AVELUMAB IN COMBINATION WITH AXITINIB FOR THE TREATMENT OF FIRST-LINE ADVANCED RENAL CELL CARCINOMA IN PORTUGAL
    Miguel, Silva L.
    Pinheiro, B.
    Lopes, R.
    Borges, M.
    Kearney, M.
    Zanotti, G.
    Hart, R.
    Smith, S.
    VALUE IN HEALTH, 2022, 25 (01) : S22 - S22
  • [40] Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers
    Atkins, Michael
    Martini, Jean-Francois
    Plimack, Elizabeth
    McDermott, David
    Puzanov, Igor
    Fishman, Mayer
    Cho, Daniel
    Vaishampayan, Ulka
    Rosbrook, Brad
    Fernandez, Kathrine
    Tarazi, Jamal
    George, Saby
    Choueiri, Toni
    CANCER RESEARCH, 2019, 79 (13)
12345